Dr. Ed Jarman (PhD)

Post Doctoral Research Fellow

  • MRC Human Genetics Unit
  • MRC Institute of Genetics & Molecular Medicine

Contact details

Address

Street

MRC Human Genetics Unit
MRC Institute of Genetics & Molecular Medicine
The University of Edinburgh
Western General Hospital
Crewe Road South

City
Edinburgh
Post code
EH4 2XU

Biography

Background

I studied for my bachelor's degree in Molecular Biology at the University of Edinburgh, here I developed a keen interest in cell signal transduction and the complexities involved in interpreting an array of external stimuli to elicit an appropriate cellular response. Following an enjoyable undergraduate degree, I began working towards my PhD at the MRC Institute of Genetics & Molecular Medicine in Edinburgh with Dr Simon Langdon. During my PhD, I applied my interest in cell signal transduction to the problem of breast cancer hypoxia, focussing on how growth factor signalling modulates the cellular response to low oxygen, a common occurence in solid tumours. I currently work as a post-doctoral researcher at the MRC Human Genetics Unit (still in Edinburgh and part of the IGMM) with Dr Luke Boulter, investigating the Wnt signalling regulator Dickkopf-1 (DKK1) in liver homeostasis and cholangiocarcinoma initiation and progression. 

Qualifications

  • Bachelor
    • 2013, Bachelor of Science with Honours - University of Edinburgh
  • Doctorate
    • 2018, Doctor of Philosophy - University of Edinburgh

Research summary

I am predominantly interested in the role of the Wnt signalling pathway in the initiation and progression of bile duct cancers (cholangiocarcinoma). I am investigating how signalling can be contolled by Wnt signalling regulators such as Dickkopf-1 (DKK1), and how signal transduction is directed down canonical and non-canonical wnt signalling pathways, both in the context of cholangiocarcinoma and in liver homeostasis.

Current research interests

My current research focuses on the role of DKK1, a negative regulator of canonical Wnt signalling. DKK1 has been shown to be up-regulated in a number of cancer types, including cholangiocarcinoma, and is associated with worse prognosis, but this appears to contradict its role as an inhibitor of Wnt signalling. Using a combination of 2D cell lines, human and mouse organoid models and in vivo genetic manipulation, I am working to identify novel DKK1 signalling pathways and ask how these pathways are perturbed in cholangiocarcinoma.

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer

Edward J. Jarman, Arran K. Turnbull, Carlos Martinez-Perez, James Meehan, Chrysi Xintaropoulou, Andrew Sims, Carol Ward, Simon P. Langdon.

Breast Cancer Research. 2019 Jan 21:10

doi: 10.1186/s13058-019-1097-0

 

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

Meehan, J, Ward, C, Turnbull, A, Bukowski-Wills, J, Finch, A, Jarman, E J, Xintaropoulou, C, Martinez-Perez, C, Gray, M, Pearson, M, Mullen, P, Supuran, C T, Carta, F, Harrison, D J, Kunkler, I H & Langdon, S

Oncotarget. 2017 Jun 27; 8(26): 42857–42875

doi: 10.18632/oncotarget.17143

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models

Martínez-Pérez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, Jarman EJ, Thomson PI, Campbell CJ, McPhail D, Harrison DJ, Langdon SP.

Br J Cancer. 2016 Apr 12;114(8):905-16

doi: 10.1038/bjc.2016.6

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models

Carol Ward, James Meehan, Peter Mullen, Claudiu Supuran, J. Michael Dixon, Jeremy S. Thomas, Jean-Yves Winum, Philippe Lambin, Ludwig Dubois, Nanda-Kumar Pavathaneni, Edward J. Jarman, Lorna Renshaw, InHwa Um, Charlene Kay, David J. Harrison, Ian H. Kunkler, and Simon P. Langdon.

Oncotarget. 2015 Sep 22; 6(28): 24856–24870

doi: 10.18632/oncotarget.4498

 

This article was published on